Quantbot Technologies LP Avadel Pharmaceuticals PLC Transaction History

Quantbot Technologies LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$12.55 - $17.22 $262,483 - $360,156	20,915 New	20,915 $353,000
Q3 2023 Nov 07, 2023	BUY	$10.3 - $15.99 $78,146 - $121,316	7,587 New	7,587 $78,000
Q3 2022 Nov 07, 2022	BUY	$2.57 - $7.31 $17,733 - $50,439	6,900 New	6,900 $34,000
Q4 2021 Feb 11, 2022	SELL	$7.34 - $11.18 $42,572 - $64,844	-5,800 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$6.49 - $9.91 $37,642 - $57,478	5,800 New	5,800 $56,000
Q1 2021 May 14, 2021	SELL	$6.61 - $10.07 $8,593 - $13,091	-1,300 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$5.03 - $7.95 $5,085 - $8,037	-1,011 Reduced 43.75%	1,300 $8,000
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $11,601 - $20,752	2,311 New	2,311 $11,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.